![](/img/cover-not-exists.png)
O-017FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO
Marmorino, F, Cremolini, C, Bergamo, F, Pella, N, Antoniotti, C, Rossini, D, Dell'Aquila, E, Masi, G, Salvatore, L, Loupakis, F, Marcucci, L, Gemma, D, Cardellino, G, Borelli, B, Ricci, V, Delfanti, SVolume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy149.016
Date:
June, 2018
File:
PDF, 73 KB
english, 2018